PMID- 35152356
OWN - NLM
STAT- MEDLINE
DCOM- 20220425
LR  - 20220425
IS  - 1437-7772 (Electronic)
IS  - 1341-9625 (Linking)
VI  - 27
IP  - 5
DP  - 2022 May
TI  - Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese 
      patients with a high-risk of gastrointestinal stromal tumor recurrence.
PG  - 921-929
LID - 10.1007/s10147-022-02135-7 [doi]
AB  - BACKGROUND: Complete surgical resection is the only treatment for resectable 
      gastrointestinal stromal tumors (GISTs). Three-year adjuvant chemotherapy (AC) is 
      recommended for patients with high-risk GISTs. However, there are scarce data on 
      this topic in Japan. We aimed to study the efficacy and safety of AC in Japanese 
      patients with high-risk GISTs. METHODS: Patients with high-risk GISTs who 
      received complete resections during 1992-2019 in our hospitals were included in 
      this retrospective study. We evaluated patients' treatments with or without AC, 
      completion rates, adverse events (AEs), recurrence-free survival (RFS), and 
      overall survival (OS). RESULTS: Overall, 89 patients categorized as high risk 
      were enrolled in this study. Fifty-five patients received AC (AC group), and 34 
      patients did not receive AC (control group). Twenty-three (41.8%) patients 
      experienced Common Terminology Criteria for Adverse Events Grade 2 or higher AEs. 
      At a median follow-up of 61.6 months, 41 (74.5%) patients completed the planned 
      treatment (including six patients with ongoing treatment), whereas 14 (25.4%) 
      patients did not complete the treatment owing to the development of AEs (nine 
      patients), patients' request (three patients), recurrence (one patient), and 
      mutational analysis (one patient). Comparing the data between the treatment and 
      control groups, the RFS rate was significantly better for the AC group 
      (P < 0.001). However, there was no significant difference in the OS rate between 
      the two groups. CONCLUSION: Postoperative AC was well tolerated by Japanese 
      patients at an acceptable rate, and its use may reduce the risk of recurrence in 
      patients with high-risk GISTs.
CI  - (c) 2022. The Author(s) under exclusive licence to Japan Society of Clinical 
      Oncology.
FAU - Ushimaru, Yuki
AU  - Ushimaru Y
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
AD  - Department of Surgery, Sakai City Medical Center, Osaka, Japan.
FAU - Takahashi, Tsuyoshi
AU  - Takahashi T
AUID- ORCID: 0000-0003-2397-1478
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan. 
      ttakahashi2@gesurg.med.osaka-u.ac.jp.
FAU - Nakajima, Kiyokazu
AU  - Nakajima K
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Teranishi, Ryugo
AU  - Teranishi R
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Nishida, Toshirou
AU  - Nishida T
AD  - Department of Surgery, Japan Community Health Care Organization Osaka Hospital, 
      Osaka, Japan.
FAU - Hirota, Seiichi
AU  - Hirota S
AD  - Department of Surgical Pathology, Hyogo College of Medicine, Hyogo, Japan.
FAU - Motoori, Masaaki
AU  - Motoori M
AD  - Department of Surgery, Osaka General Medical Center, Osaka, Japan.
FAU - Omori, Takeshi
AU  - Omori T
AD  - Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.
FAU - Kawabata, Ryohei
AU  - Kawabata R
AD  - Department of Surgery, Sakai City Medical Center, Osaka, Japan.
FAU - Nishikawa, Kazuhiro
AU  - Nishikawa K
AD  - Department of Surgery, Sakai City Medical Center, Osaka, Japan.
FAU - Saito, Takuro
AU  - Saito T
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Yamashita, Kotaro
AU  - Yamashita K
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Tanaka, Koji
AU  - Tanaka K
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Makino, Tomoki
AU  - Makino T
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Yamamoto, Kazuyoshi
AU  - Yamamoto K
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Kurokawa, Yukinori
AU  - Kurokawa Y
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Eguchi, Hidetoshi
AU  - Eguchi H
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
FAU - Doki, Yuichiro
AU  - Doki Y
AD  - Department of Gastroenterological Surgery, Osaka University Graduate School of 
      Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220212
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
RN  - 0 (Antineoplastic Agents)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - *Gastrointestinal Stromal Tumors/drug therapy/pathology/surgery
MH  - Humans
MH  - Imatinib Mesylate/therapeutic use
MH  - Japan
MH  - Neoplasm Recurrence, Local/chemically induced/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Adjuvant chemotherapy
OT  - High-risk GIST
OT  - Imatinib
EDAT- 2022/02/14 06:00
MHDA- 2022/04/26 06:00
CRDT- 2022/02/13 20:37
PHST- 2021/09/13 00:00 [received]
PHST- 2022/02/01 00:00 [accepted]
PHST- 2022/02/14 06:00 [pubmed]
PHST- 2022/04/26 06:00 [medline]
PHST- 2022/02/13 20:37 [entrez]
AID - 10.1007/s10147-022-02135-7 [pii]
AID - 10.1007/s10147-022-02135-7 [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2022 May;27(5):921-929. doi: 10.1007/s10147-022-02135-7. Epub 
      2022 Feb 12.